"Access is dwindling for many older, off-patent, essential drugs as companies use an emerging strategy to acquire therapies in niche markets where there are few or no alternatives, and then jack up the price.
Authors of a perspective p"...
None.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 12/1/2014
Additional Naglazyme Information
Report Problems to the Food and Drug Administration
Find out what women really need.